Agreement - March 7, 2023
Affibody and Chiesi Group collaborate
Affibody and Chiesi Group have announced the execution of a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s technology. Under the terms of the agreement, the parties will collaborate closely to progress up to three programs based on Affibody molecules against undisclosed targets for respiratory diseases. Chiesi will […]
Agreement - February 23, 2023
AstraZeneca enters license agreement with KYM Biosciences
The companies have entered into a global exclusive license agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancer. Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialisation of CMG901 globally. CMG901 CMG901 is currently being evaluated in a […]
Agreement - February 20, 2023
Aqilion enters licensing and research collaboration with Merck
Aqilion has announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. “We are delighted and proud to announce this collaboration with Merck as it validates our business strategy of generating highly innovative discovery projects in combination with […]
Agreement - January 17, 2023
Bristol Myers Squibb and Karolinska University Hospital enter collaboration
Karolinska University Hospital’s cancer department has signed an agreement with Bristol Myers Squibb to start an oncology and hematology research collaboration focusing on advancing research and generating data with an aim to deliver innovative therapies for patients. The organizations will centralize the work through a steering committee consisting of experts from both organizations to discuss […]
Agreement - January 10, 2023
CombiGene and Zyneyro enter collaboration agreement
The two companies have entered into a collaboration agreement regarding the continued development of Zyneyro’s peptide- and AAV-based treatment of chronic pain conditions. The agreement with Zyneyro is a cooperation agreement that means that Zyneyro and CombiGene share the project’s costs and revenues equally. “The concept of being able to give the pain-relieving peptide directly […]
Agreement - January 5, 2023
Alligator and Orion initiate second immuno-oncology program
Alligator Bioscience has announced an expansion to its research collaboration and license agreement with Orion Corporation, to discover and develop together new bispecific antibody cancer therapeutics. The collaboration has been expanded to add the development of a second bispecific antibody using Alligator’s bispecific RUBY platform, where Alligator will provide validated monospecific binders for one target […]
